On October 16, Dr. Juan Carlos Almagro, Director of Antibody Research at UDIBI, participated in the “Festival of Biologics 2024” in Basel, Switzerland. This event gathered international experts to advance the development of innovative biological therapies.

During his presentation, Dr. Almagro highlighted the antibody discovery platforms developed in Mexico and the key advancements stemming from them. He also successfully led the roundtable discussion on bispecific antibodies and the session on “checkpoint inhibitors”. These accomplishments reflect the hard work and dedication of the UDIBI team at IPN, showcasing Mexico’s capability to conduct top-tier research and development.

The “Festival of Biologics” serves as a vital platform that connects industry, academia, and biotechnology to tackle challenges in the biopharmaceutical sector. Dr. Almagro’s participation underscores UDIBI’s commitment to driving scientific innovation and placing Mexico on the global biotechnology map.

Proudly polytechnic, proudly UDIBI, 100% Mexican!

On October 2-3, UDIBI proudly participated in the TechPharmaNet, event held at the Marquis Reforma Hotel in Mexico City. This prestigious event brought together executives and experts from across the pharmaceutical industry, creating a platform for sharing knowledge and forging valuable professional connections in the areas of research, development, and commercialization.

Dr. Sonia Mayra Pérez-Tapia, our Director, delivered an insightful presentation showcasing UDIBI’s strengths in technology, infrastructure, and regulatory compliance. She also highlighted the groundbreaking progress in the development of therapeutic antibodies. One of our key achievements is the creation of a fully Mexican-developed, innovative antibody from our own libraries, which has shown promising results in eradicating tumors in non-clinical models. This antibody is now set to be transferred to a national pharmaceutical company for further development, positioning UDIBI as a leader in the creation of advanced biotechnological products aimed at treating various diseases, including cancer.

TechPharmaNet 2024 served as a vital opportunity for fostering collaboration and growth between the pharmaceutical and biotech sectors, reaffirming UDIBI’s commitment to advancing research and developing new therapies that will contribute to better global health outcomes.

On July 2^nd the Federal Commission for the Protection against Sanitary Risks of Mexico (COFEPRIS) granted UDIBI the extension of its authorization as a laboratory for the assessment of Preclinical Biosimilarity, valid through July 2026. Since it complied with the provisions of the legal framework required for the authorization of third-party laboratories of COFEPRIS. UDIBI was first authorized to conduct biosimilarity tests on 2015, and from 2017 to date has maintained its authorization as a Third-party laboratory for the assessment of Preclinical Biosimilarity, in compliance of the current regulatory and legal framework. Recently, on March 4^th, 2024, UDIBI obtained a License that authorizes it as a Testing and Control Laboratory auxiliary to health regulation (Health License: 09 011 13 0002) which along with its authorization as a “Third-party Test Laboratory” which has been in effect since 2017, allows UDIBI to have a broad analytical framework to carry out physicochemical, microbiological, biological and immunological analyzes to evaluate medicines, medical devices and other health supplies.

Mexico participated in the Bio International Convention 2024, from June 3 to 6 in San Diego California, thanks to the support of the Ministry of Foreign Affairs (SRE) and the Mexican Consulate in San Diego, California,

BIO is one of the most important conventions worldwide in promoting innovation, research and attracting investments in the field of biotechnology.

Around 21,000 participants from more than 60 countries gathered for this edition. The Mexican delegation was represented by important institutes and companies of the biotechnology sector such as Cecype, Epic-CRO, Incide, Pisa Pharmaceutical, New Genesis, Organon, Pragmatec , Network of Technology Transfer Offices, Tijuana Economic Development Corporation, Udelá and UDIBI.

UDIBI’s Directors; Dr Sonia Mayra Pérez Tapia and Dr. Juan Carlos Almagro, and Business Development Manager; Dr. Sergio Torres Pérez, attended this important convention to show the capabilities of UDIBI and establish new collaboration opportunities with biopharmaceutical companies in the world.

Mexico’s presence at the convention places it as a relevant and strategic player in the global biotechnology panorama, since numerous biotechnology companies, academic institutions and cutting-edge research centers have been developed in our country, which ranked it as one of the three most important countries in Latin America in this industry, as the result of the collaboration between the public and private sectors and academia.

Related notes:
https://www.gob.mx/sre/prensa/mexico-participa-en-la-bio-international-convention-2024?tab=

https://www.excelsior.com.mx/nacional/industria-farmaceutica-mexicana-bio-international-convention-2024/1656130).

On Wednesday, December 6, 2023, Dr. Perez Tapia participated in the meeting of
Innovative Professors of the IPN, where she presented the talk entitled "Innovation and
Technological Developments in Health from the IPN, thereby showing that in the UDIBI we
take biotechnological innovation in Mexico to the next level.
Watch the video in: https://www.youtube.com/watch?v=kN5MM6xA9zI

At UDIBI we are proud that our graduate students in Immunology, Ivette Mendoza and Ismael Trejo, attended to the “18th International Congress of Immunology” in Cape Town, South Africa, we celebrate these enriching international experiences and we are sure that they put up “The technology at the service of our homeland”.

On Tuesday, November 28th, Dr. Sonia Mayra Perez Tapia attended to the ” Cycle of talks on Biotechnology / Biopharmaceuticals”, talking about: “Biosimilars source of innovation in Mexico”, where she shared details about the innovation model of the UDIBI.

On November 28, 2023, our collaborator, Dr. Carlos Lopez, gave a talk on “Hemoderivatives: Basic concepts” in the course “Sanitary regulation applicable to hemoderivative medicines” of AMEPRES.

M. en C. Alejandra Montes, collaborator of UDIBI, was present at the symposium “Spectral Cytometry”, at the Universidad Distrital de Colombia, where she shared about the importance of the flow cytometer in the research and development of therapeutic antibodies.

On November 24, Dr. Sonia Mayra Perez Tapia was present at the facilities of the Tecnologico de Monterrey campus CDMX where she presented a talk entitled “Quality and regulatory aspects for clinical trials focused on biotherapeutics”.

Last Friday, November 24, Dr. Sonia Mayra Perez Tapia was present at the “29th Anniversary Academic Conference of the Hospital del Niño Morelense”, with the theme: “Realities of the transfer factor”.

Transferon Oral® is an outstanding contribution of the National Polytechnic Institute, which has had an impact on the health of thousands of people with immunological diseases at a national and international level. It has a patent registration in favor of the IPN in Mexico and 36 other countries, including the United States, Canada and the European Union.

Read more in https://www.ipn.mx/…/gaceta…/2023/08/g-60-aniv-1739.pdf

UDIBI-IPN, extends congratulations to Dr. Aliesha Araceli Gonzalez Arenas from the Institute of Biomedical Research of the UNAM, for winning first place in the “CANIFARMA 2023 Award” in the category of Clinical Research.

Congratulations!

Dr. Mayra Perez Tapia participated in the “8th International Meeting on Health Regulation”, with the presentation “Regulatory Overview of Biotechnological and Biosimilar Medicines in LATAM”.

On November 15, Dr. Mayra Perez Tapia was at Biosimilars LatAm Mexico 2023, where she shared important points about the construction of the future of Biosimilars in Mexico and LatAm through academia.

An enriching visit to the UDIBI-ENCB-IPN of the Instituto Nacional de Cancerología-ESE of Colombia, where we explored our capabilities and outlined exciting routes of collaboration to advance research and new technologies in the fight against cancer.

From November 6 to 8, we were present at the “LVI National, X International and IV Virtual Congress of Pharmaceutical Sciences”, showing our capabilities, technologies and services.

The work of researcher Andrés Moreno-Estrada and his team from the Mexican Biobank Project was presented. By genotyping 6,057 individuals from all 32 Mexican states, they ensured representation from indigenous communities. In addition, Jonathan Marchini and colleagues share results from the Mexico City Prospective Study, which genotyped and sequenced 140,000 adults in two districts of the capital. Together, these papers reveal the genetic histories of the Mexican population and offer insights into genetic risks associated with disease. #MexicanGenomics #ScientificResearch.

Comment: https://www.nature.com/nature/volumes/622/issues/7984

On October 26, 2023, Dr. Mayra Perez Tapia was present at the “Festival Internacional del Libro y la Lectura San Lorenzo Tezonco”, with the theme “Women, Science and Entrepreneurship: Inspiring the Future”.

On October 26, 2023, Dr. Sonia Mayra Perez Tapia was present at the “44th Update Meeting in Pediatrics”, with the topic:

“Immunomodulation with Transfer Factor (Transferon Oral ®) in Allergic diseases”.

On October 25, 2023, Dr. Mayra Perez Tapia participated in the Symposium “50 years of DNA Recombinant Technology: Its impact on human biology, medicine, laboratory and pharmacy”, which was held at the National Academy of Medicine of Mexico with the theme “From gene to cell therapy”.

From October 18 to 20, UDIBI was present at the “XII Annual Congress of RedOTT Mexico” in the city of Irapuato, Guanajuato, where we showed that at UDIBI we take biotechnological innovation in Mexico to the next level.

Our strategic partner GlobalBio extends the agreement with the antibody engineering company Antiverse, for the development of checkpoints inhibitors in cancer, with two anti-PD1 antibodies in preclinical development.

Read more: https://ow.ly/J2Fz50PYQ4N

From October 5 to 7, 2023, in Oaxaca, Mexico; UDIBI was present at the “XIII National Congress of Virology”, organized by the Mexican Society of Virology, where we participated in different activities such as sponsors, presentation of oral papers and posters, thus showing that in UDIBI we take biotechnological innovation in Mexico to the next level.

From October 4 to 5, 2023 UDIBI-IPN was present at the “Second edition of the IPN Innovation Fair”, where we showed the technology and innovation of our products and services.

From September 26th to 28th, 2023 UDIBI-IPN was present at BIOSPAIN 2023, the most important biotechnology forum in Europe, where we showed our capabilities, technologies and services.

On September 22, Dr. Sonia Mayra Perez Tapia participated in the round table “Health in Mexico” where she shared her knowledge and point of view on the subject.

On September 14, Dr. Sonia Mayra Perez Tapia participated in the symposium “COVID-19” of the “XX National Congress of Biotechnology and Bioengineering” with the topic “Isolation, optimization and preclinical development of a broad spectrum neutralizing anti-SARS-CoV2 antibody”.

From September 11 to 15, 2023, in Ixtapa Zihuatanejo, UDIBI was present at the “XX National Congress of Biotechnology and Bioengineering”, organized by the Mexican Society of Biotechnology and Bioengineering, where we participated in different activities such as sponsors, presentation of oral papers and in the symposium entitled “COVID-19”.

On September 13, Dr. Sonia Mayra Pérez Tapia participated in Biosimilars LatAm – Europe 2023, with the talk “Similarity: a source of innovation in Mexico”, where she shared her knowledge, contributions and point of view about biosimilars in our country.

On September 5, Ignacio Mejia Calvo, UDIBI Services Manager, participated in the XL International Book Fair of the National Polytechnic Institute with the presentation “COVID-19, an opportunity for innovation in the IPN”.

Last Monday, August 28th, Dr. Mayra Perez Tapia participated in the article “Opinion: Biotechnology dependence or self-sufficiency”, for EL ECONOMISTA, where she commented on the basic premises towards self-sufficiency in biotechnology-based medicine. To read the article click here

On August 16, Dr. Sonia Mayra Pérez Tapia participated in Biosimilars LatAm – Brazil 2023, with the talk “Similarity: a source of innovation in Mexico”, where she shared her knowledge, contributions and point of view about biosimilars in our country.

Last Friday, August 4, Dr. Sonia Mayra Perez Tapia participated in the “1st Latin American Forum on Advanced Therapies” where she shared knowledge about the “Challenges in clinical trials for the regulation of advanced therapies”, if you missed it click here https://ow.ly/WLJ450PmaHQ

On July 13, 2023 Dr. Mayra Perez Tapia was present in the radio program “La Mujer Actual con Janett Arceo” where she shared relevant information about the “Myths and realities of post-COVID sequels”, if you missed it click here https://www.youtube.com/watch?v=fci-16elotM

Last Saturday, July 8, Dr. Sonia Mayra Perez Tapia participated in the “XXX COMPEDIA Congress” where she shared the latest advances in the research and development of our product Transferon Oral®, a proudly polytechnic product!

On July 5, Dr. Sonia Mayra Perez Tapia was present at the inauguration of the Tenth National Congress of Health Regulation Professionals, an event presided by the Head of the Ministry of Health in Guerrero, Aibé Ibarez Castro.

More information at https://guerrero.quadratin.com.mx/inaugura-aide-ibarez…/

On June 22nd, Dr. Sonia Mayra Pérez Tapia was interviewed in the program ¡Huélum!- Flavors and Fragrances of the IPN, where she talked about the characterization of Transferon (Transfer Factor), you can see the transmission here.

https://www.youtube.com/watch?v=D4fVYMgicwY

Last June 22, 2023 Dr. Sonia Mayra Perez Tapia participated in the InnovaPRIS session “Advanced Therapy Medicinal Products”, which seeks to exchange ideas and experiences to improve the welfare of the population by giving visibility to innovative practices in regulated industries.

To watch the transmission click on  https://ow.ly/ACEI50OYoiT

Listen to the seventh episode of FIFARMA’s podcast #Innovatibles!

In the episode, Yaneth Giha, Executive Director of FIFARMA and Sonia Mayra Perez Tapia, Executive Director of UDIMEB and recognized innovator expert in immunology, talk about the importance of Intellectual Property as the basis to boost innovation and development in Latin America.

🎧 Listen here and share this podcast so that more people can explore Latin American talents and knowledge.

🔸Spotify: https://ow.ly/IKZn50OOJkp

🔸Apple: https://ow.ly/ges550OOJki

From June 5 to 8, UDIBI was present at the most important biotechnology convention in the world, “BIO International Convention 2023” in the city of Boston. This event was attended by more than 14,000 people from industry, academia and government representatives from countries with important advances in biotechnology, including Mexico. UDIBI connected with the global ecosystem of the biotech industry, associations, educational institutions and investors, creating great collaborations for the future.

From June 4 to 8, 2023, in the city of Santiago de Queretaro, Queretaro, UDIBI was present at the “XXV National Congress of Immunology”, organized by the Mexican Society of Immunology, where we participated in different activities such as sponsors, poster presentations, oral presentations and the symposium entitled “Innovation and Technological Development”, which was attended by international speakers.

Last Saturday June 3rd in Guadalajara, Jalisco, Dr. Sonia Mayra Perez Tapia was present at the Congress of the Mexican College of Clinical Immunology and Allergy A.C. where she spoke on the topic “Immunomodulation with Transfer Factor (Transferon Oral ®) and Allergic Diseases”.

On May 31, 2023, in the Auditorium of the Interdisciplinary Professional Unit of Biotechnology of the National Polytechnic Institute (UPIBI-IPN), took place the first day of projects of the “Technological Postgraduate in Vaccines and Biotherapeutics”, with the participation of Dr. Sonia Mayra Perez Tapia and collaborators of the UDIBI, see the transmission in the link https://www.youtube.com/watch?v=GNN8izf2qb4

On May 25, 2023, Dr. Sonia Mayra Perez Tapia participated in the 1st Symposium on Oncology 2023 at the Hospital Infantil de Mexico Federico Gomez.

1st Symposium of Oncology 2023 at the Children’s Hospital of Mexico Federico Gomez, with the topic “Platforms for the development of cancer therapies in Mexico”.

On May 22, Dr. Sonia Mayra Perez Tapia participated in the virtual symposium of the Mexican Pharmaceutical Association, with the presentation “The future of MABs; therapeutics developing research platforms”.

Therapy Summit (PEGS) in Boston. The world’s largest gathering of protein engineering and biotherapeutics experts, event with comprehensive programming that covered all aspects of biologic drug development with in-depth presentations on protein and antibody engineering, immunotherapy, oncology, expression, analytics, immunogenicity, and other interesting topics of biotherapeutics.

April 19^th, 2023. After over three years in which the pandemic caused by the SARS-CoV-2 coronavirus made it necessary to impose restrictions worldwide in order to prevent contagion. The Director General of the World Health Organization, transmitted the report of the International Health Regulations Emergency Committee that determined that COVID-19 is no longer a health emergency.

view more

On April 26^th, the Biosimilars LatAm forum, hosted by the Jack Leckerman Company, was held in Bogota, Colombia. UDIBI participated in this forum with the talk on the success story: UDIBI as a link between academia, industry and regulation, talk given by our Service Manager, QFB. Ignacio Mejía Calvo.

view more

From April 24^th to 29^th, the Second National Week against Sanitary Risks was held in Acapulco, Mexico. In this forum our Director, Dr. Sonia Mayra Perez Tapia participated as moderator of the panel: “The art of regulation as a way to access to new treatments”.

view more

On April 18^th, the results of the CONACYT’s Frontier Science 2023 call were announced, in which the research proposal “Assessment of immunomodulatory effects of oral extracellular monomeric Ubiquitin (Ubme) in allergic rhinitis: efficacy and pharmacokinetics”, developed by our research group for Immunomodulators led by Dr. Luis Alberto Vallejo Castillo, was awarded. CONGRATULATIONS!

view more

On March 15^th, UDIBI attended to “Latin American Innovation and Patents Exhibition” hosted by the Ministry of Foreign Affairs, the Mexican Agency for International Development Cooperation (AMEXCID) and the Network of Technology Transfer Offices, Mexico (redOTT). This event was held as part of the Science and Technology for Society Forum 2023, on its Latin America and Caribbean Chapter.

view more

Duirng the first week of March, our General Director, Dr. Sonia Mayra Perez Tapia, participated as part of the retinue of scientists and diplomats who accompanied the Minister of Foreign Affairs; Marcelo Ebrard on his work tour to ImmunoACT Laboratories in Mumbai, India. The aim of this visit was to follow up on the agreement signed on November 8th, 2022 among the National Institute of Medical Sciences and Nutrition “Salvador Zubirán” (INCMNSZ), the National Polytechnic Institute (IPN), and ImmunoACT, intended to promote technology transfer CAR-T (Chimeric Antigen Receptor) cell therapies for the treatment of cancer patients from India to Mexico. CAR-T cell therapy consists in obtaining cells from the patient’s immune system (T lymphocytes) to be genetically modified at the laboratory to make them capable to recognize and fight cancer cells; once modified, the cells (CAR-T) will be administered back to the patient to fight the disease.

view more

What did we learn from the pandemic?

view interview

Jun 20, 2022

The UDIBI-IPN present at the Mexico stand with cutting-edge biotechnological developments and products at #BIO2022.

Jun 03, 2022

Lecture by Dr. Sonia Mayra Pérez Tapia, on the Use of Leukocyte Extracts in Allergic Diseases.
Date: June 03
Location: Monterrey, Nuevo Leon
Registration: https://cmica.bycri.com/registration/

Jun 02, 2022

Participation of Dr. Sonia Mayra Pérez Tapia, in the Academic Session of the
National Congress of the Mexican College of Clinical Immunology and Allergy.

May 23, 2022

Participation of Dr. Sonia Mayra Pérez, in the Digital program with Rocío Braujer, where she discussed her experience as a businesswoman and the obstacles that came her way in her technological-scientific career.

May 17, 2022

Participation of Dr. Sonia Mayra Pérez Tapia, in the Science Factor program, where she shared with us the journey through the research has gone through to carry out the transfer factor, and to remind us of the importance of education in science, technology and innovation in Mexico.

Marzo 08 del 2022

Participación de la UDIBI en el encuentro PRONAII del 25 y 26 de marzo de inmunoterapia multidisciplinaria y Leucemia infantil en el Centro de Educación Contínua Ing. Eugenio Méndez Docurro de la CDMX

Febrero 15 del 2022

Dr. Mayra Pérez Tapia, Directora Ejecutiva de UDIBI, Inmunóloga ENCB.

Fecha: 17 de febrero

Hora: 12:00 am

Reflexión 24 informativo con Esaú Nájera.

January 13, 2022

Interview with Dr. Sonia Mayra Pérez Tapia, CEO of UDIBI: Beginning of the development and preclinical evaluation of a mixture of recombinant antibodies against all variants of concern, including the Wuhan, Delta and importantly, against the Omicron variant.

January 13, 2022

Interview with Dr. Juan Carlos Almagro, director of R&d at UDIBI. He shared on N+Live of Noticieros Televisa, the beginning of a preclinical development and evaluation of recombinant antibodies against all variants of concern, including Wuhan, Delta and, importantly, against the Omicron variant.

Diciembre 01 del 2021

En UDIBI nos unimos a la celebración del Día del Químico Farmacéutico. Muchas felicidades.

Noviembre 24 del 2021

LA BIOTECNOLOGÍA EN LA DETECCIÓN DEL VIRUS SARS-CoV-2: logros y perspectivas futuras, el 24 de noviembre en de 2021 en el foro 7 del instituto de química de la UNAM. Comentarios a cargo de la Dra. Sonia Mayra Pérez Tapia

ver más

Noviembre 17 del 2021

Conferencia magistral “La importancia del monitoreo de la inmunidad contra SARS-CoV-2 para un regreso seguro a las actividades” llevada a cabo el 17 de noviembre del 2021 por la Dra. Sonia Mayra Pérez Tapia.

ver más

Noviembre 17 del 2021

Ponencia con título “Transferencia de Tecnología, Innovación y Desarrollo”. A cargo de la Dra. Sonia Mayra Pérez Tapia. Se llevó a cabo el 17 de noviembre en la Ciudad de México a las 14:50 hora de México.

ver más

Noviembre 2 al 4 del 2021

Presentación de cartel con título “Isolation and optimization of neutralizing antibodies against SAR-CoV-2 using ALTHEA Gold Plus Libraries^TM . Exposición a cargo del Dr. Juan Carlos Almagro y la Dra. Sonia Mayra Pérez Tapia la cual se llevó a cabo en Barcelona-España del 2 al 4 de noviembre.

ver más

Septiembre 28 del 2020 a Enero 29 del 2021

Clase online – Impartido por la Dra.Martha Pedraza y Dra.Sonia Mayra Pérez

ver más

Abril 26 al 29 del 2021

PARTICIPACIÓN INTEGRANTES UDIBI CON POSTERS Y PONENCIAS DRA MAYRA

ver más

Abril 22 al 24

PARTICIPACIÓN CON STAND, WTC, CDMX.

ver más

Marzo 26

Se pospone hasta nuevo aviso

ver más

Marzo 8

Participación en temas del 8 de marzo

ver más

Febrero 27

Conferencia de producción de productos biotecnológicos

ver más

Febrero 17

Foro Especialistas en torno al impulso de las mujeres en áreas STEM

ver más